Vivos Therapeutics (NASDAQ: VVOS) has signed a definitive agreement to acquire The Sleep Center of Nevada (SCN), the largest sleep center operator in Nevada, for up to $9 million. The deal includes $6 million in cash, $1.5 million in Vivos common stock at closing, and potential additional $1.5 million in stock tied to performance milestones.
SCN, founded in 2008, serves approximately 3,000 new patients monthly and has generated high seven-figure annual net revenues. The center operates seven locations with nearly 50 beds for overnight sleep testing. About 90% of SCN patients test positive for OSA, with 95% typically referred for CPAP, traditional oral devices, or surgical options.
The acquisition, expected to close in Q2 or Q3 2025, aligns with Vivos' new marketing and distribution model following its June 2024 alliance with Rebis Health. The company aims to expand its FDA-cleared oral appliance treatments for OSA directly to patients seeking alternatives to CPAP or surgery.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.